R. Yu

发表

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors

P. LoRusso, K. Papadopoulos, M. Beeram, 2014, Cancer Chemotherapy and Pharmacology.

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors

P. Hegde, A. Tolcher, K. Papadopoulos, 2014, Investigational New Drugs.

Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).

J. Tabernero, Yoon-Koo Kang, A. Ohtsu, 2013 .

Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

H. Wildiers, P. LoRusso, J. Ferrero, 2016 .

Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis.

J. Ware, P. LoRusso, W. Fairbrother, 2012, Toxicological sciences : an official journal of the Society of Toxicology.

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

A. Tolcher, F. Peale, K. Papadopoulos, 2016, Clinical Cancer Research.

Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).

Zhaoyang Wen, Brigitte Maurer, Vickie Tsui, 2012, Journal of medicinal chemistry.

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

Mallika Singh, W. Forrest, H. Koeppen, 2010, Nature Biotechnology.

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) versus treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

Sung-Bae Kim, H. Wildiers, I. Krop, 2016 .

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Sung-Bae Kim, H. Wildiers, P. LoRusso, 2014, The Lancet. Oncology.

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

P. Tassone, Y. Bang, Yoon-Koo Kang, 2014, British Journal of Cancer.

A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors.

P. Hegde, P. LoRusso, A. Patnaik, 2011, Journal of Clinical Oncology.

Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.

A. Tolcher, F. Peale, K. Papadopoulos, 2013 .

O-0021PERTUZUMAB PHARMACOKINETICS AND SAFETY IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE ADVANCED GASTRIC CANCER (AGC)

P. Tassone, Y. Bang, Yoon-Koo Kang, 2013 .

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

Sung-Bae Kim, H. Wildiers, I. Krop, 2016, International journal of cancer.

Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis.

P. LoRusso, W. Fairbrother, H. Wong, 2012, Toxicological sciences : an official journal of the Society of Toxicology.